Oslo, Norway, February 15th, 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company is preparing the first-in-man study of its lead drug candidate APC148, end of this year. Embarking on the clinical phase 1 program will be a major achievement and inflexion point for the company. In 2-year time, the company will have documented a significant part of the efficacy and safety needed for a market authorisation. This will make Adjutec attractive to partners and strengthen the commercial positioning of company. To strengthen the support of partnering activities Adjutec is happy to announce that Ton Berkien has been elected to the company board.
Ton Berkien has a background from Saxion University of Applied Science, Scandinavian International Management Institute and Harvard Business School. He has worked 20 years in the international pharma industry in various companies including Amgen, Takeda/Nycomed and Ferring in business development and corporate development positions, covering licensing and M&A. His experience covers deal-making with J&J, Amgen and Almirall in territories including the US, Europe and a number of growth markets, e.g. China. At present he is CBO of Ultimovacs (Norway) and serves as Chairman of the Board of Gedea, a company in Lund, Sweden. Ton has a Dutch and Swedish nationality and lives in Sweden.
“The main milestones for Adjutec in the coming 2-3 years is to secure funding and strike a deal with a partner to take APC148 to the market. The huge experience of Ton Berkien in deal-making including his investor network, will be of great value to Adjutec. We are looking forward to working with him on the board of the company”, comments Chair of Board Nicolaj Weiergang.
Full PR available here